Score recurrence and progression risk for non-muscle-invasive bladder cancer with the published EORTC risk tables.
Result
How to use this tool
Use the pathology and cystoscopy findings at diagnosis.
Primary tumours score 0; recurrent tumours score by yearly rate.
T1, CIS and G3 each raise progression risk sharply.
A tumour can have a high recurrence risk with a low progression risk, and vice versa.
Formula & worked example
A single tumour under 3 cm, primary, Ta, no CIS and G1 scores 0 for recurrence and 0 for progression: published recurrence about 15% at 1 year and 31% at 5 years, progression about 0.2% and 0.8%.
Limitations — read this before you rely on it
Educational use of the published EORTC tables only. Outputs are historical population statistics, not personal prognoses, and are not medical advice. They do not account for BCG or other treatment, pathology review or individual follow-up.
Frequently asked questions
Non-muscle-invasive bladder cancer: cancer confined to the bladder lining (Ta, T1 or CIS) without muscle invasion.
The chance of recurrence (tumour coming back) and progression (advancing to muscle-invasive disease) at 1 and 5 years.
They were developed before modern BCG maintenance was universal, so treated patients often fare better than the tables suggest.
Carcinoma in situ is flat, high-grade disease with a high risk of progression, hence 6 progression points.
No. Treatment and surveillance decisions belong to the urology team with full pathology.